Written Authority Required Drugs

Asthma – severe eosinophilic asthma

The Pharmaceutical Benefits Scheme (PBS) subsidises benralizumab or mepolizumab for patients with uncontrolled severe eosinophilic asthma.

Patient eligibility

The PBS subsidises treatment with benralizumab or mepolizumab under the National Health Act 1953, Section 100 – Highly Specialised Drugs (HSD) Program, for patients with uncontrolled severe eosinophilic asthma.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing benralizumab or mepolizumab.

Section 100 arrangements

These items are only available for day admitted patients, non-admitted patients or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

These items aren't PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Toxicity and severity descriptors

When demonstrating a patient’s intolerance to prior treatment, use the severe asthma toxicity and severity descriptors with the authority application. 

Treatment specifics

Patients must be treated by a respiratory physician, clinical immunologist, allergist or general physician with expertise managing severe asthma to be eligible for PBS subsidised treatment with benralizumab and mepolizumab.

Applications

Initial treatment

Apply for initial authority approval to prescribe PBS subsidised benralizumab or mepolizumab to treat uncontrolled severe eosinophilic asthma in writing and either:

All applications must include the completed:

Initial grandfather treatment

For patients who received non-PBS subsidised benralizumab treatment before 1 December 2018 for uncontrolled severe eosinophilic asthma, apply for initial grandfather authority approval in writing and either:

All applications must include the completed:

Continuing treatment

Apply for authority approval to continue PBS subsidised benralizumab or mepolizumab to treat uncontrolled severe eosinophilic asthma in writing and either:

Applications must include the completed:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 22 February 2019